MicroQuin

MicroQuin is a pre-clinical biotechnology company with first-in-class, lead compounds that use two technologies to kill breast cancers

MicroQuin is a pre-clinical biotechnology company with first-in-class, lead compounds that use two technologies to kill breast cancers; one specifically targets cancers and another selectively induces cell death. MicroQuin plans to optimise its lead compound, MQ001, and initially focus on treating Triple Negative Breast Cancers (TNBCs), which accounts for 15-20% of all breast cancer cases and has the lowest rate of survival beyond 5 years.